These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

886 related items for PubMed ID: 24160898

  • 1. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.
    World J Surg Oncol; 2013 Oct 25; 11():284. PubMed ID: 24160898
    [Abstract] [Full Text] [Related]

  • 2. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.
    Mod Pathol; 2013 Jul 25; 26(7):922-9. PubMed ID: 23429602
    [Abstract] [Full Text] [Related]

  • 3. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
    Neurology; 2013 Oct 22; 81(17):1515-22. PubMed ID: 24068788
    [Abstract] [Full Text] [Related]

  • 4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.
    Klin Onkol; 2017 Oct 17; 30(5):361-371. PubMed ID: 29031038
    [Abstract] [Full Text] [Related]

  • 8. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.
    Neuro Oncol; 2014 Dec 17; 16(12):1630-8. PubMed ID: 25028501
    [Abstract] [Full Text] [Related]

  • 9. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.
    Clin Cancer Res; 2010 Mar 01; 16(5):1597-604. PubMed ID: 20160062
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K, Wang YY, Ma J, Wang JF, Li SW, Jiang T, Dai JP.
    Asian Pac J Cancer Prev; 2014 Mar 01; 15(24):10893-8. PubMed ID: 25605197
    [Abstract] [Full Text] [Related]

  • 11. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
    Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C, Brazil L, Sadler G, Beaney R, Sibtain N, King A, Bodi I, Jones C, Ashkan K, Al-Sarraj S.
    Neuro Oncol; 2013 Dec 01; 15(12):1635-43. PubMed ID: 24158110
    [Abstract] [Full Text] [Related]

  • 12. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.
    J Neurooncol; 2012 Dec 01; 110(3):325-33. PubMed ID: 23015095
    [Abstract] [Full Text] [Related]

  • 13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.
    J Neurooncol; 2016 Sep 01; 129(3):505-514. PubMed ID: 27401154
    [Abstract] [Full Text] [Related]

  • 14. Molecular profile of oligodendrogliomas in young patients.
    Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C.
    Neuro Oncol; 2011 Oct 01; 13(10):1099-106. PubMed ID: 21937591
    [Abstract] [Full Text] [Related]

  • 15. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.
    J Neurooncol; 2012 May 01; 107(3):617-31. PubMed ID: 22287028
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M, German Glioma Network.
    Clin Cancer Res; 2013 Sep 15; 19(18):5146-57. PubMed ID: 23918605
    [Abstract] [Full Text] [Related]

  • 19. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.
    J Neurooncol; 2011 Nov 15; 105(2):345-57. PubMed ID: 21643842
    [Abstract] [Full Text] [Related]

  • 20. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.
    Neuro Oncol; 2013 Jun 15; 15(6):775-82. PubMed ID: 23486687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.